Tonix Pharmaceuticals, Inc.
509 Madison Ave.
219 articles with Tonix Pharmaceuticals, Inc.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today the pricing of an underwritten public offering with expected total gross proceeds of $9.0 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company.
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced financial results for the quarter ended September 30, 2019, and provided an overview of recent operational highlights.
Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA Meeting
Tonix Pharmaceuticals Holding Corp. announced that in the currently-enrolling Phase 3 study of Tonmya®* for the treatment of posttraumatic stress disorder, the timing of the primary endpoint analysis has been changed from Week 4 to Week 12 and the Company plans to add an interim analysis that allows for a potential sample size adjustment, based on guidance from its recent Breakthrough Therapy Type B Clinical Guidance meeting with the U.S. Food and Drug Administration.
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it will effect a 1-for-10 reverse stock split of its outstanding common stock.
Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 10,449,203 to the Company on October 22, 2019.
Tonix Pharmaceuticals Holding Corp. announced that it has joined the Alliance for Biosecurity The Alliance is a coalition of biopharmaceutical companies and laboratory/academic partners that promotes a strong public-private partnership to ensure medical countermeasures are available to protect public health and enhance national health security.
Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting
New Phase 3 Trial of Tonmya® for the treatment of PTSD to Commence First Quarter 2019
Shares of Tonix Pharmaceuticals shot up 25 percent in premarket trading this morning after the company announced there may be a future for its late-stage posttraumatic stress disorder treatment Tonmya after a Phase III trial was halted early in July following a data review showed an inadequate re...
Tonix Pharmaceuticals is halting its Phase III clinical trial of Tonmya in military related posttraumatic stress disorder (PTSD).
Gen. Grange assumes the seat held by Stuart Davidson, who has stepped down from the position of company director that Mr. Davidson has held since 2011.
Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya (Cyclobenzaprine HCl Sublingual Tablets)
Tonix is in Phase 3 development of Tonmya, a FDA-designated Breakthrough Therapy for the treatment of PTSD.
Tonix Pharmaceuticals Announces Publication Reporting Synthesis, Construction and Characterization of a Potential Smallpox-Preventing Vaccine Candidate TNX-801 (Live Horsepox Virus From Cell Culture)
The research was conducted in conjunction with scientists from the University of Alberta, a leading Canadian research university.
Ms. Morris brings to the senior leadership team a deep understanding of drug development and corporate strategy from her tenure at Tonix as well as over a decade of experience in the financial industry.
At September 30, 2017, Tonix had cash and cash equivalents of $29.3 million. Net cash used in operating activities for the third quarter was $5.0 million.
Tonix Pharmaceuticals Reports Outcomes From U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya (Cyclobenzaprine HCI Sublingual Tablets) for PTSD
Tonix is in Phase 3 development of Tonmya, an FDA-designated Breakthrough Therapy for the treatment of PTSD.
Tonix Pharma Receives European Patent For The Active Ingredient In Tonmya (Cyclobenzaprine HCL Sublingual Tablets)
Tonix Pharma Presented Additional Phase II Clinical Results In Military-Related PTSD And Design Of Ongoing Phase III Trial At The 2017 Military Health System Research Symposium
Tonix Pharma To Present Additional Phase II Clinical Results And Design Of Ongoing Phase III Trial In Military-Related PTSD At The 2017 Military Health System Research Symposium
Tonix Pharma Announces Conditional Acceptance Of Tonmya As Proposed Brand Name For TNX-102 SL (Cyclobenzaprine HCL Sublingual Tablets) For The Treatment Of PTSD